TransCode Therapeutics CFO Tom Fitzgerald Plans To Retire; John Tattory To Serve As Interim Finance Chief, Effective Immediately
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer,